Mallinckrodt plc
Case Number:
1:20-bk-12522
Court:
Nature of Suit:
Firms
- Rosner Law Group LLC
- Post & Schell
- Consovoy McCarthy
- Sherrard Roe
- Pryor Cashman
- Finson Law Firm
- Morris James
- Phillips Lytle
- Ciardi Ciardi
- Law Office of Curtis A. Hehn
- Abernathy Roeder
- Michael Best & Friedrich LLP
- Sussman Shank
- FrankGecker
- Frazer PLC
- Potter Anderson
- Margolis Edelstein
- Motley Rice
- Pachulski Stang
- WilmerHale
- Richards Layton
- Andrews & Thornton
- Sirlin Lesser
- Carothers & Hauswirth
- Cole Schotz
- ASK LLP
- Landis Rath
- Chipman Brown
- Meyers & Flowers
- Stradley Ronon
- Elliott Greenleaf
- Barrack Rodos
- Smith Katzenstein
- Obermayer Rebmann
- Chamberlain Hrdlicka
- Miller & Martin
- Skikos Crawford
- Bailey & Glasser
- Perdue Brandon
- Dechert LLP
- Cooch & Taylor
- Martzell Bickford
- Kennedys Law LLP
- Halperin Battaglia
- Connolly Gallagher
- Leech Tishman
- Moses & Singer
- Hunton Andrews
- Gibson Dunn
- Beasley Firm
- Gilbert LLP
- Mehri & Skalet
- Cooley LLP
- Caplin & Drysdale
- Crowell & Moring
- Simon Greenstone
- Bilzin Sumberg
- Goldstein & McClintock
- Reed Smith
- McDermott Will & Emery
- Morris Nichols
- Berger Mcdermott
- Miller Nash LLP
- A&O Shearman
- Brown & Connery
- Skadden Arps
- Robbins Geller
- Robbins Russell
- Kramer Levin
- Doroshow Pasquale
- Katten Muchin
- Whiteford Taylor
- Shipman & Goodwin
- Bielli & Klauder
- Duane Morris
- Benesch
- Sonosky Chambers
- Robinson & Cole
- Greenberg Traurig
- Warner Norcross
- Arnold & Porter
- Womble Bond
- Powell Firm
- ArentFox Schiff LLP
- David Christian Attorneys LLC
- Sullivan Hazeltine
- Schulte Roth
- Bartimus Frickleton
- Parkowski Guerke
- Quinn Emanuel
- Sequor Law
- Fox Swibel
- Saul Ewing
- Stinson LLP
- Montgomery McCracken
- Morgan Lewis
- Stutzman Bromberg
- Togut Segal
- Maschoff Brennan
- McCarter & English
- Akin Gump
- Lewis Brisbois
- Friedman Kaplan
- Abrams & Bayliss
- Napoli Shkolnik
- Monzack Mersky
- Dorsey & Semrau
- Manatt Phelps
- ArentFox Schiff
- Fox Rothschild
- Hughes Socol
- Blank Rome
- DLA Piper
- Rawlings & Associates PLLC
- Ashby & Geddes
- Faegre Drinker
- Dentons
- Morgan & Morgan
- Binder & Schwartz
- Klehr Harrison
- Buchalter APC
- Eiseman Levine
- Hogan McDaniel
- O'Melveny & Myers
- Brown Rudnick
- Raines Feldman
- Herrick Feinstein
- K&L Gates
- Kleinberg Kaplan
- Flaster Greenberg
- Campbell & Levine
- Chiesa Shahinian
- Carlton Fields
- Levenfeld Pearlstein
- Hackett Feinberg
- Stevens & Lee
- Rolnick Kramer
- Cozen O'Connor
- MacElree Harvey
- Eimer Stahl
- Haviland Hughes
- Hagens Berman
- Ross Aronstam
- Linebarger Goggan
- Ross Smith & Binford
- Lathrop GPM
- FrankelWyron
- Taft Stettinius
- Foley & Lardner
- Covington & Burling
- Bragar Eagel
- Munsch Hardt
- Ogletree Deakins
- Keller Postman
- Law Firm of Russell R. Johnson III
- Fishman Haygood
- Lippes Mathias
- Clark Hill
- Lowenstein Sandler
- Norton Rose
- Paul Hastings
- Jones Day
- Leader Berkon
- Paul Weiss
- Lowey Dannenberg
- Singer & Levick
- Kobre & Kim
- Goodwin Procter
- Sullivan & Cromwell
- Wachtell Lipton
- Wilson Sonsini
- Seward & Kissel
- Kay Casto
- Young Conaway
- Cross & Simon
- Henrichsen Law Group
- Jenner & Block
- Hobbs Straus
- Latham & Watkins
- White & Case
- Willkie Farr
Companies
- Medco Health Solutions Inc.
- Integrated Benefits Inc.
- Henry Schein Inc.
- Berkshire Hathaway Energy GT&S
- CVS Health Corp.
- Merck & Co. Inc.
- Third Point LLC
- PCI Pharma Services
- Perrigo Co. PLC
- Province LLC
- U.S. Bancorp
- Iron Mountain Inc.
- Aetna Inc.
- CNA Financial Corp.
- Paulson & Co. Inc.
- LifeWallet
- Quantitative Investment Management LLC
- Endo International PLC
- Lumen Technologies Inc.
- Covidien PLC
- Anda Inc.
- Conduent Inc.
- Covance Inc.
- Rain for Rent Inc.
- Olin Corp.
- Syntax Systems Ltd.
- Ferguson Enterprises Inc.
- HealthCor Partners Management LP
- Wells Fargo & Co.
- New York State Electric & Gas Corp.
- Ernst & Young LLP
- Ironshore Inc.
- CSX Corp.
- Optum Inc.
- Express Scripts Holding Co.
- Zinc Health Services LLC
- Catalent Inc.
- JPMorgan Chase & Co.
- United Association
- Microsoft Corp.
- Guggenheim Partners LLC
- United BioSource Corp.
- Deloitte Touche Tohmatsu Ltd.
- Humana Inc.
- Stretto Inc.
- The Goldman Sachs Group Inc.
- Cencora Inc.
- Ducera Partners LLC
- University of Toledo
- Allianz Global Investors GmbH
- Callidus Software Inc.
- University of Iowa
- Oracle Corp.
- Fresenius Kabi AG
- OptumRx Inc.
- Berkshire Hathaway Inc.
- ASM Capital LP
- SAP AG
- Concur Technologies, Inc.
- Cardinal Health Inc.
- Fresenius SE & Co. KGaA
- Liberty Mutual Insurance Group
- Bristol-Myers Squibb Co.
- Deutsche Bank AG
- Southeastern Freight Lines Inc.
- AlixPartners LLP
- McKesson Corp.
- Johnson Controls International PLC
- State Teachers Retirement System of Ohio
- Duke Energy Corp.
- Constellation Energy Corp.
- Johnson & Johnson
- Cephalon Inc.
- Morgan Stanley
- American Federation of State County & Municipal Employees
- NERA Economic Consulting Inc.
- Iqvia Holdings Inc.
- Jefferies Financial Group Inc.
- Old Dominion Freight Line Inc.
- Teva Pharmaceutical Industries Ltd.
Government Agencies
- Ohio Department of Taxation
- Missouri Department of Revenue
- Texas Comptroller of Public Accounts
- U.S. Securities and Exchange Commission
- State of Michigan
- City of Syracuse, New York
- Texas Workforce Commission
- Minnesota Department of Revenue
- Mississippi Division of Medicaid
- State of Indiana
Sectors & Industries:
-
November 19, 2021
Acthar Claimants Seek Mallinckrodt Chapter 11 Vote Probe
A group with antitrust claims against Mallinckrodt on Friday asked a Delaware bankruptcy judge to appoint an examiner to investigate what it claims are thousands of questionable votes cast for the drugmaker's Chapter 11 plan on behalf of asbestos injury claimants.
-
November 18, 2021
Mallinckrodt Ch. 11 Plan Hearing Won't Restart Monday
The Delaware bankruptcy judge overseeing Mallinckrodt's Chapter 11 case Thursday granted requests to delay the resumption of the drugmaker's plan confirmation hearing, saying he first needs to digest claims it engaged in drug price manipulation.
-
November 17, 2021
Mallinckrodt Denies Manipulating Acthar Market
Mallinckrodt closed its defense against claims it inflated the price of its Acthar gel on Wednesday, with witnesses saying that the drugmaker didn't suppress a competing product and that the speaking fees it paid to doctors didn't increase sales.
-
November 16, 2021
Mallinckrodt Says Insurers' Acthar Claims Off By $317M
An expert witness for Mallinckrodt told a Delaware bankruptcy judge Tuesday that two insurers seeking more than $317 million in damages wouldn't be owed any more than $2.6 million even if their claims that the drugmaker suppressed competition for its Acthar gel were true.
-
November 15, 2021
Mallinckrodt Exec Says Acthar Price Hikes Were Necessary
A Mallinckrodt executive defended the pricing and marketing of the drugmaker's Acthar gel on Monday as a pair of insurers presented a Delaware judge with the last of their evidence that Mallinckrodt engaged in a yearslong scheme to drive up Acthar's cost.
-
November 12, 2021
Insurers Say Mallinckrodt Sales Strategy Cost Them $320M
A pair of insurers seeking antitrust damages from drugmaker Mallinckrodt over the sales of its Acthar gel put their expert witnesses before a Delaware bankruptcy judge on Friday, claiming they overpaid more than $320 million for Acthar over the past year.
-
November 08, 2021
Insurers Claim Mallinckrodt Inflated Acthar Price By $300M
A pair of health insurers told a Delaware bankruptcy judge Monday that Mallinckrodt PLC owes them more than $300 million because of the drugmaker's alleged efforts to keep a cheaper alternative to its Acthar infantile spasm drug off the market.
-
November 05, 2021
Mallinckrodt Cleared On $94M Ch. 11 Bond Penalty
A Delaware bankruptcy judge on Friday found Mallinckrodt does not owe a $94 million payment to noteholders, saying the creditors should not get a "windfall" simply as a result of the drugmaker's Chapter 11 filing.
-
November 04, 2021
Mallinckrodt Can Duck Acthar Royalties In Chapter 11
A bankruptcy judge in Delaware Thursday ruled drugmaker Mallinckrodt can use Chapter 11 to escape royalty payments for the sale of its Acthar Gel medication as the confirmation hearing for the company's restructuring plan continued.
-
November 02, 2021
Antitrust Group Says Mallinckrodt Plan Lacks Sufficient Votes
A group with antitrust claims against drugmaker Mallinckrodt challenged the vote approving the company's Chapter 11 plan on Tuesday, but lost a bid to get counsel for the unsecured creditors on the stand to address the vote solicitation process.